Repository logo
 
Publication

The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union/European Economic Area

2019-12-10Journal article Open access
Simple item page
dc.contributor.authorCole, Michelle J
dc.contributor.authorQuinten, Chantal
dc.contributor.authorJacobsson, Susanne
dc.contributor.authorDay, Michaela
dc.contributor.authorAmato-Gauci, Andrew J
dc.contributor.authorWoodford, Neil
dc.contributor.authorSpiteri, Gianfranco
dc.contributor.authorUnemo, Magnus
dc.contributor.authorThe Euro-GASP network
dc.date.accessioned2020-08-04T23:54:44Z
dc.date.available2020-08-04T23:54:44Z
dc.date.issued2019-12-10
dc.descriptionEuro-GASP network: Angelika Stary, Maria Haller, Ruth Verbrugge, Tania Crucitti, Soteroulla Soteriou, Despo Pieridou, Susan Cowan, Steen Hoffmann, Jevgenia Epstein, Jelena Viktorova, Ndeindo Ndeikoundam, Agathe Goubard, Peter Kohl, Susanne Buder, Viviane Bremer, Eva Tzelepi, Vasileia Konte, Eszter Balla, Mária Dudás, Guðrún Sigmundsdóttir, Guðrún Svanborg Hauksdóttir, Derval Igoe, Brendan Crowley, Barbara Suligoi, Paola Stefanelli, Gatis Pakarna, Violeta Mavcutko, Christopher Barbara, Jackie Maistre Melillo, Alje Van Dam, Birgit Van Benthem, Ineke Linde, Hilde Kløvstad, Thea Bergheim, Slawomir Majewski, Beata Mlynarczyk-Bonikowska, Jacinta Azevedo, Maria José Borrego, Peter Pavlik, Peter Truska, Irena Klavs, Samo Jeverica, Julio Vazquez, Mercedes Diez, Inga Velicko, Magnus Unemo, Gwenda Hughes, Kirstine Eastickpt_PT
dc.descriptionEuro-GASP network: Maria José Borrego (Departamento de Doenças Infeciosas do INSA)pt_PT
dc.description.abstractBackground: European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) antimicrobial resistance (AMR) data are used to inform gonorrhoea treatment guidelines; therefore the data need to be robust and representative. We assessed the extent to which Euro-GASP reflects national measures of the AMR situation for Neisseria gonorrhoeae across the European Union/European Economic Area (EU/EEA). Methods: We compared data from Euro-GASP with published national gonococcal AMR data from 15 countries for azithromycin, cefixime and ciprofloxacin for the period 2009 to 2013 and performed Poisson regression to identify differences (p < 0.05) between the proportions of resistant isolates. The 2014 Euro-GASP AMR data for each country (n = 19) were weighted to account for differences in the distribution of patient characteristics between Euro-GASP and EU/EEA epidemiological gonorrhoea surveillance data. Data were compared to determine whether estimates of resistance levels differed with regards to the 5% threshold used to assess the clinical utility of first-line gonorrhoea treatments. We assessed the quality of decentralised testing by comparing AMR data for isolates tested both centrally and in the participating laboratories, and by evaluating external quality assessment (EQA) performance. Results: There was no significant difference for azithromycin, cefixime and ciprofloxacin resistance when Euro-GASP country data were compared with data from national reports. Weighting slightly altered the Euro-GASP AMR estimates (by between - 4.7 and 4.7% from the unweighted estimates). Weighting resulted in greater changes in estimates of resistance to azithromycin (from - 9.5 to 2.7%) and ciprofloxacin (from - 14.8 to 17.9%) in countries with low isolate numbers and low completeness of reporting (n = 3). Weighting caused AMR levels to fall below or above the 5% threshold for cefixime or azithromycin, respectively in only two countries. Susceptibility category data submitted from the decentralised Euro-GASP laboratories were concordant with the Euro-GASP data (> 90%). EQA performance was also good; < 5% of the minimum inhibitory concentration (MIC) results differed by > 4-fold from the modal MIC of the EQA isolate. Conclusions: The overall prevalence of AMR reported by Euro-GASP reflects closely the AMR situation for N. gonorrhoeae in the EU/EEA. Euro-GASP data can be used to provide robust AMR estimates to inform the European guideline for the management of gonorrhoea.pt_PT
dc.description.sponsorshipThe study was funded by the European Centre for Disease Prevention and Control (Framework Contract No. ECDC/2013/015). The funding body contributed to the design of the study, the analysis and interpretation of the data and to the writing of the manuscript.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationBMC Infect Dis . 2019 Dec 10;19(1):1040. doi: 10.1186/s12879-019-4631-xpt_PT
dc.identifier.doi10.1186/s12879-019-4631-xpt_PT
dc.identifier.issn1471-2334
dc.identifier.urihttp://hdl.handle.net/10400.18/7184
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherBioMed Central Ltd.pt_PT
dc.relation.publisherversionhttps://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-019-4631-xpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectAnti-Bacterial Agentspt_PT
dc.subjectAzithromycinpt_PT
dc.subjectCefiximept_PT
dc.subjectCiprofloxacinpt_PT
dc.subjectDrug Resistance, Bacterialpt_PT
dc.subjectEuropean Unionpt_PT
dc.subjectGonorrheapt_PT
dc.subjectHumanspt_PT
dc.subjectMicrobial Sensitivity Testspt_PT
dc.subjectNeisseria gonorrhoeaept_PT
dc.subjectInfecções Sexualmente Transmissíveispt_PT
dc.titleThe European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union/European Economic Areapt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue1pt_PT
oaire.citation.startPage1040pt_PT
oaire.citation.titleBMC Infectious Diseasespt_PT
oaire.citation.volume19pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
s12879-019-4631-x.pdf
Size:
942.75 KB
Format:
Adobe Portable Document Format
Download

Collections

DDI - Artigos em revistas internacionais